As hypothesized, patients with higher genetic levels (GR1, specific mutations) exhibited significant frontal and temporal atrophy associated with earlier and greater cognitive impairments than GR2 patients (carriers of risk tau and APOE variants) and patients with sporadic forms of the disease (GR3). This evidence concerns the gene APOE and Cognitive impairment.